A global analysis of the reconstitution of PTEN function by translational readthrough of PTEN pathogenic premature termination codons
- PMID: 33600059
- DOI: 10.1002/humu.24186
A global analysis of the reconstitution of PTEN function by translational readthrough of PTEN pathogenic premature termination codons
Abstract
The PTEN tumor suppressor gene is mutated with high incidence in tumors and in the germline of patients with cancer predisposition or with macrocephaly associated with autism. PTEN nonsense mutations generating premature termination codons (PTC) and producing nonfunctional truncated PTEN proteins are frequent in association with human disease. However, there are no studies addressing the restoration of full-length PTEN proteins from the PTC-mutated PTEN gene by translational readthrough. Here, we have performed a global translational and functional readthrough analysis of the complete collection of PTEN PTC somatic or hereditary mutations found in tumors or in the germline of patients (disease-associated PTEN PTCome), and we set standards for the analysis of the potential of readthrough functional reconstitution in disease-relevant genes. Our analysis indicates that prevalent pathogenic PTEN PTC mutations are susceptible to PTEN functional restoration in response to readthrough-inducing compounds. Comprehensive readthrough analyses of disease-associated PTComes will be valuable tools for the implementation of readthrough-based precision interventions in specific groups of patients.
Keywords: nonsense mutation; premature termination codon; translational readthrough; tumor suppressor.
© 2021 Wiley Periodicals LLC.
Similar articles
-
Therapeutic Potential of Translational Readthrough at Disease-Associated Premature Termination Codons From Tumor Suppressor Genes.IUBMB Life. 2025 May;77(5):e70018. doi: 10.1002/iub.70018. IUBMB Life. 2025. PMID: 40317855 Free PMC article. Review.
-
Potentiation by Protein Synthesis Inducers of Translational Readthrough of Pathogenic Premature Termination Codons in PTEN Isoforms.Cancers (Basel). 2024 Aug 13;16(16):2836. doi: 10.3390/cancers16162836. Cancers (Basel). 2024. PMID: 39199607 Free PMC article.
-
Induction of Translational Readthrough on Protein Tyrosine Phosphatases Targeted by Premature Termination Codon Mutations in Human Disease.Methods Mol Biol. 2024;2743:1-19. doi: 10.1007/978-1-0716-3569-8_1. Methods Mol Biol. 2024. PMID: 38147205
-
Factors Affecting Readthrough of Natural Versus Premature Termination Codons.Adv Exp Med Biol. 2023;1415:149-155. doi: 10.1007/978-3-031-27681-1_23. Adv Exp Med Biol. 2023. PMID: 37440028 Review.
-
Molecular Insights into Determinants of Translational Readthrough and Implications for Nonsense Suppression Approaches.Int J Mol Sci. 2020 Dec 11;21(24):9449. doi: 10.3390/ijms21249449. Int J Mol Sci. 2020. PMID: 33322589 Free PMC article. Review.
Cited by
-
Novel anti-PTEN C2 domain monoclonal antibodies to analyse the expression and function of PTEN isoform variants.PLoS One. 2023 Aug 1;18(8):e0289369. doi: 10.1371/journal.pone.0289369. eCollection 2023. PLoS One. 2023. PMID: 37527256 Free PMC article.
-
Therapeutic Potential of Translational Readthrough at Disease-Associated Premature Termination Codons From Tumor Suppressor Genes.IUBMB Life. 2025 May;77(5):e70018. doi: 10.1002/iub.70018. IUBMB Life. 2025. PMID: 40317855 Free PMC article. Review.
-
Exploring absent protein function in yeast: assaying post translational modification and human genetic variation.Microb Cell. 2021 Jul 2;8(8):164-183. doi: 10.15698/mic2021.08.756. eCollection 2021 Aug 2. Microb Cell. 2021. PMID: 34395585 Free PMC article. Review.
-
Therapeutic targeting of TP53 nonsense mutations in cancer.Ups J Med Sci. 2024 May 27;129. doi: 10.48101/ujms.v129.10719. eCollection 2024. Ups J Med Sci. 2024. PMID: 38863730 Free PMC article. Review.
-
Combinatorial biosynthesis of novel gentamicin derivatives with nonsense mutation readthrough activity and low cytotoxicity.Front Pharmacol. 2025 Apr 24;16:1575840. doi: 10.3389/fphar.2025.1575840. eCollection 2025. Front Pharmacol. 2025. PMID: 40342992 Free PMC article.
References
REFERENCES
-
- Alimonti, A., Carracedo, A., Clohessy, J. G., Trotman, L. C., Nardella, C., Egia, A., Salmena, L., Sampieri, K., Haveman, W. J., Brogi, E., Richardson, A. L., Zhang, J., & Pandolfi, P. P. (2010). Subtle variations in Pten dose determine cancer susceptibility. Nature Genetics, 42(5), 454-458. https://doi.org/10.1038/ng.556
-
- Alvarez-Garcia, V., Tawil, Y., Wise, H. M., & Leslie, N. R. (2019). Mechanisms of PTEN loss in cancer: It's all about diversity. Seminars in Cancer Biology, 59, 66-79. https://doi.org/10.1016/j.semcancer.2019.02.001
-
- Andrés-Pons, A., Rodríguez-Escudero, I., Gil, A., Blanco, A., Vega, A., Molina, M., Pulido, R., & Cid, V. J. (2007). In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN. Cancer Research, 67(20), 9731-9739. https://doi.org/10.1158/0008-5472.CAN-07-1278
-
- Asiful Islam, M., Alam, F., Kamal, M. A., Gan, S. H., Wong, K. K., & Sasongko, T. H. (2017). Therapeutic suppression of nonsense mutation: An emerging target in multiple diseases and thrombotic disorders. Current Pharmaceutical Design, 23(11), 1598-1609. https://doi.org/10.2174/1381612823666161122142950
-
- Atkinson, J., & Martin, R. (1994). Mutations to nonsense codons in human genetic disease: Implications for gene therapy by nonsense suppressor tRNAs. Nucleic Acids Research, 22(8), 1327-1334. https://doi.org/10.1093/nar/22.8.1327
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials